分子品質管理の市場規模：製品タイプ別、分析物タイプ別、用途別、エンドユーザー別、地域別、範囲および予測

分子品質管理市場の規模と予測

分子品質管理市場規模は、2023年に2億418万米ドルと評価され、2024年から2031年にかけてCAGR 6.55%で成長し、2031年には3億3,919万米ドルに達すると予測されています。分子品質管理は、ポリメラーゼ連鎖反応（PCR）やDNAシーケンシングのような分子生物学技術の信頼性と正確性を検証するために使用される標準とプロセスで構成されます。これらの管理には、特定の遺伝的形質を持つ既知のプリセットサンプルを使用することが含まれ、実験室の機器、試薬、および全体的なアッセイ条件の性能を検証するためのベンチマークとして機能します。主な目的は、分子検査プロセスにおける不正や欠陥を発見し、結果の正確性と再現性を確保することです。

さらに、医療診断では正確な患者診断を提供するために、法医学では刑事司法制度のためにDNAプロファイリングの完全性を維持するために、研究機関では研究を検証し、複数の分野にまたがる科学的発見に貢献するために、重要な役割を果たしています。

分子品質管理市場力学

分子品質管理市場を形成している主な市場力学

主な市場促進要因

正確な診断に対する需要の高まり：

早期診断、オンタイム治療のための正確な診断とカスタマイズされた医薬品に対する需要が高まっています。その結果、分子検査はこれらの領域で重要な役割を果たしており、品質管理を実施することで検査結果の信頼性が高まり、診断や治療方針の決定の精度に対する信頼性が高まる。

慢性疾患の有病率の増加：

がん、糖尿病、感染症などの慢性疾患の蔓延が拡大していることも、意欲をかきたてる一面です。これらの疾病の負担が増加するにつれ、分子診断薬に対する需要も増加し、診断検査の精度と信頼性を確保するための包括的な品質管理の実施が必要となります。

分子技術の進歩：

分子技術、特に次世代シーケンシング（NGS）やデジタルPCRの進歩は、業界の拡大を後押ししています。このような技術開発により、これらの先端技術を用いて実施される検査の精度を確保するため、それぞれのニーズに合わせてカスタマイズされた品質管理を確立する必要があります。

主な課題

限られた認識と採用：

強固な品質管理に関する知識と導入が限られていることが、大きな課題となっています。先進的な診断法に対する関心は高まっているが、厳格な品質管理の必要性と利点に関する知識は、特に資源に乏しい環境では普遍的なものではないかもしれないです。このような認識不足は、管理体制の未活用につながり、検査結果の正確性と信頼性を損なう可能性があります。

厳しい規制と複雑な実施：

FDAやEMAのような規制機関による厳格な規則の適用は諸刃の剣です。これらの規則は分子診断薬の正確性と信頼性を確保するために必要である一方、製造業者とエンドユーザーの双方にとってコストと複雑さを増すものでもあります。経営資源が限られている小規模検査施設では、コンプライアンスがより困難となり、これらの規則に適切に従う能力が制限される可能性があります。

細分化された市場：

多くの製造業者によって供給されるコントロールの種類が多岐にわたるため、消費者がそれぞれの要件に最適なコントロールを比較・選択することは困難です。プラットフォームやアッセイ間で共通の対照物質や基準値がないため、品質管理手順の妨げとなり、複数の診断プロセスへのスムーズな統合を妨げています。

主要動向：

ポイントオブケアでの採用拡大：

もう一つの重要な開発は、ポイントオブケア（POC）診断の利用拡大です。分子検査が患者にとってより身近になるにつれて、分散化された環境向けに設計されたポータブルで使いやすい品質管理システムが求められています。このことは、個別化されカスタマイズされた管理という一般的な動向と一致しており、特定の検査室のニーズや検査に管理ソリューションを適応させる方向へのシフトを示しています。その結果、ポイント・オブ・ケア（POC）診断薬の使用の増加は、分子品質市場における重要な開拓となっています。

自動化と効率化の重視：

自動化と効率性の重視は現在進行中の動向であり、検査室では手順の合理化と全体的な効率性向上のために自動化技術の導入が進んでいます。この自動化重視の傾向は品質管理にも及んでおり、メーカーは自動制御システムを導入して人為的ミスを排除し、データの一貫性を高めることで、最終的に分子検査の信頼性を高めています。

分子品質管理市場の地域分析

分子品質管理市場の詳細な地域分析は以下の通り：

北米：

北米は予測期間中、分子品質管理市場を独占すると予測されます。分子品質管理市場における北米の優位性は、確立されたヘルスケアインフラの存在と、厳しい規制の枠組みを遵守して製品開発や研究開発活動に注力している市場プレイヤーの存在による。

この地域には、近代的な研究所や診断技術とともに、強固で先進的なヘルスケアシステムがあります。こうした基盤が、診断検査の信頼性と正確性を保証する分子品質規格の普及に適した環境を生み出しています。

北米は食品医薬品局（FDA）が示すように厳しい規制に従っています。これらの規制は、品質管理ソリューションの導入を促進し、標準化された高品質の分子診断の文化を奨励しています。規制遵守への取り組みは診断結果の正当性と信頼性を向上させ、同地域の市場における主導的地位に貢献しています。

さらに、北米にはアボット・ラボラトリーズやロシュ・ダイアグノスティックスのような有力な市場プレーヤーが存在し、市場力学に大きな影響を与えています。これらの業界プレーヤーは、この地域の技術開拓とイノベーションに貢献し、世界の分子品質管理市場への道を開いています。

欧州：

自動化統合の利点と品質管理の重要性に関する意識の高まりが、この地域の強力なヘルスケアシステムに、現在の厳しい規制に準拠した分子品質管理の採用を促しています。

近代的な診断能力を備えた強固なヘルスケアシステムの存在は、分子品質管理の採用にとって理想的な環境を生み出すと予想されます。

厳しい規制の枠組みは、検査室での検査方法における高いレベルの品質保証を保証します。欧州政府が患者の安全性と正確な診断を優先する中、信頼できる分子品質基準の必要性は依然として高いです。

さらに、欧州では自動化と品質管理技術の向上がますます普及しています。自動化は効率を向上させるだけでなく、人為的ミスの可能性を減少させ、高い分子診断基準を維持するというこの地域のコミットメントに合致しています。これらすべての要因が重なり、欧州は分子品質管理市場において第2位の支配的地位を占めています。

アジア太平洋：

アジア太平洋地域は、医療インフラが急成長し、あらゆる年齢層で慢性疾患が増加していること、特に高齢化人口が増加していることから、市場推計・予測期間中、分子品質管理市場において最も高いCAGRで成長すると推定されます。これに加えて、政府と多国籍および地域の品質管理メーカーが提供する支援と資金が、現在の市場拡大を後押しする上で重要な役割を果たしています。

この地域のヘルスケア・インフラは大きく成長し、高度な医療施設や診断能力への投資も拡大しています。このような拡大は、新しい分子診断技術の導入と応用に不可欠であり、品質管理の必要性を生み出しています。

慢性疾患に対する意識の高まりと、信頼性の高い診断法への重点の高まりが、この地域の分子品質管理に対する需要を後押ししています。人々の健康意識が高まるにつれて、信頼性が高く正確な診断機器への需要が高まり、品質管理へのニーズが高まる。

さらに、アジア太平洋地域には国際的な品質管理メーカーと地域的な品質管理メーカーが存在するため、アクセス性と入手性が向上し、分子品質管理市場の成長につながります。

目次

第1章 世界の分子品質管理市場のイントロダクション

• 市場概要
• 調査範囲
• 前提条件

第2章 エグゼクティブサマリー

第3章 VERIFIED MARKET RESEARCHの調査手法

• データマイニング
• 検証
• 一次資料
• データソース一覧

第4章 分子品質管理の世界市場展望

• 概要
• 市場力学
  • 促進要因
  • 抑制要因
  • 機会
• ポーターのファイブフォースモデル
• バリューチェーン分析

第5章 分子品質管理の世界市場、製品別

• 概要
• 機器別コントロール
• 独立コントロール

第6章 分子品質管理の世界市場：分析物タイプ別

• 概要
• 単一分析物コントロール
• 複数分析物コントロール

第7章 分子品質管理の世界市場：用途別

• 概要
• 感染症診断
• 腫瘍学検査
• 遺伝子検査
• その他

第8章 分子品質管理の世界市場：エンドユーザー別

• 概要
• 診断研究所
• 病院
• 体外診断用医薬品メーカーおよび受託研究機関
• 学術・研究機関
• その他のエンドユーザー

第9章 分子品質管理の世界市場：地域別

• 概要
• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • その他欧州
• アジア太平洋
  • 中国
  • 日本
  • インド
  • その他アジア太平洋地域
• 世界のその他の地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 世界の分子品質管理市場の競合情勢

• 概要
• 企業市場ランキング
• ベンダー情勢
• 主な発展戦略

第11章 企業プロファイル

• Abbott Laboratories
• Roche Diagnostics
• Thermo Fisher Scientific
• Qiagen
• Beckman Coulter
• Siemens Healthineers
• Bio-Rad Laboratories
• Agilent Technologies

第12章 主な発展

• 製品の上市／開発
• 合併と買収
• 事業拡大
• パートナーシップと提携

第13章 付録

• 関連調査

Molecular Quality Controls Market Size And Forecast

Molecular Quality Controls Market size was valued at USD 204.18 Million in 2023 and is projected to reach USD 339.19 Million by 2031, growing at a CAGR of 6.55% from 2024 to 2031. Molecular quality controls comprise standards and processes used to verify the reliability and correctness of molecular biology techniques like polymerase chain reaction (PCR) and DNA sequencing. These controls include the use of known, preset samples with certain genetic traits that serve as benchmarks for validating the performance of laboratory equipment, reagents, and overall assay conditions. The primary objective is to uncover any irregularities or flaws in the molecular testing process, ensuring the accuracy and reproducibility of the results.

Furthermore, they play an important role in medical diagnostics to provide accurate patient diagnoses, in forensics to maintain DNA profiling integrity for the criminal justice system, and in research, labs to validate studies and contribute to scientific discoveries across multiple disciplines.

Molecular Quality Controls Market Dynamics

The key market dynamics that are shaping the Molecular Quality Controls Market include:

Key Market Drivers

Rising Demand for Accurate Diagnostics:

There is an increasing demand for accurate diagnostics and customized medicines for early diagnosis of offer on-time treatment. As a result, molecular tests play an important role in these domains, and implementing quality controls increases the dependability of test results, instilling greater confidence in the accuracy of diagnoses and treatment decisions.

Increasing Prevalence of Chronic Diseases:

Another motivating aspect is the growing prevalence of chronic diseases like cancer, diabetes, and infectious disorders. As the burden of these illnesses increases, so does the demand for molecular diagnostics, necessitating the implementation of comprehensive quality controls to ensure diagnostic test accuracy and reliability.

Advancements in Molecular Technologies:

Advances in molecular technologies, particularly next-generation sequencing (NGS) and digital PCR, help to drive industry expansion. These technological developments necessitate the establishment of customized quality controls adapted to their specific needs, ensuring the accuracy of tests performed using these advanced technologies.

Key Challenges:

Limited Awareness and Adoption:

Limited knowledge and adoption of robust quality controls provide a significant challenge. While there is a growing interest in advanced diagnostics, knowledge of the need and advantages of tight quality controls may not be universal, particularly in resource-constrained settings. This lack of awareness can lead to the underutilization of controls, compromising the accuracy and dependability of test results.

Stringent Regulations and Complex Implementation:

The application of strict rules by regulatory agencies like the FDA and EMA is a two-edged sword. While these rules are necessary to ensure the accuracy and reliability of molecular diagnostics, they also add to the costs and complexity for both manufacturers and end users. Smaller laboratories with limited resources may find compliance more difficult, limiting their capacity to properly follow these rules.

Fragmented Market:

The wide range of control types supplied by many manufacturers makes it difficult for consumers to compare and select the best controls for their unique requirements. The lack of common control materials and reference values across platforms and assays hampers quality control procedures and prevents smooth integration into multiple diagnostic processes.

Key Trends:

Growing Adoption in Point-of-Care Settings:

Another significant development is the increased use of point-of-care (POC) diagnostics. As molecular testing becomes more accessible to patients, there is a demand for portable and user-friendly quality control systems designed for decentralized settings. This is consistent with the general trend of personalized and tailored controls, indicating a shift toward adapting control solutions to specific laboratory needs and tests. As a result, the increased use of point-of-care (POC) diagnostics is a significant development in the molecular quality market.

Focus on Automation and Efficiency:

The emphasis on automation and efficiency is an ongoing trend, with laboratories increasingly implementing automated technology to streamline procedures and improve overall efficiency. This emphasis on automation extends to quality control, with manufacturers implementing automated control systems to eliminate human error and enhance data consistency, ultimately increasing the reliability of molecular testing.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Molecular Quality Controls Market Regional Analysis

Here is a more detailed regional analysis of the Molecular Quality Controls Market:

North America:

North America is estimated to dominate the Molecular Quality Controls Market during the forecast period. North America's dominant position in the Molecular Quality Controls Market is driven by the presence of well-established healthcare infrastructure and market players who are focusing on developing products and conducting research and development activities in compliance with, tight regulatory frameworks.

The region has a solid and advanced healthcare system, along with modern laboratories and diagnostic technologies. This foundation creates a climate suitable to the widespread use of molecular quality standards, which ensure diagnostic test reliability and correctness.

North America follows severe regulatory regulations, as shown by the Food and Drug Administration (FDA). These regulations promote the implementation of quality control solutions, encouraging a culture of standardized and high-quality molecular diagnostics. The commitment to regulatory compliance improves the legitimacy and dependability of diagnostic results, which contributes to the region's leading market position.

Furthermore, the presence of prominent market players like Abbott Laboratories and Roche Diagnostics in North America has a significant impact on market dynamics. These industry players contribute to the region's technological developments and innovation, paving the way for the worldwide molecular quality control market.

Europe:

Growing awareness regarding the benefits of integration of automation and importance of quality control is encouraging the strong healthcare systems to adopt molecular quality controls complying with the current stringent regulations in the region.

The presence of robust healthcare systems with modern diagnostic capabilities is anticipated to create an ideal environment for the adoption of molecular quality controls.

A tight regulatory framework, ensures a high level of quality assurance in laboratory testing methods. As European governments prioritize patient safety and precise diagnosis, the need for dependable molecular quality standards remains high.

Furthermore, automation and improved quality control technologies have become increasingly popular in Europe. Automation not only increases efficiency but also reduces the chance of human error, which aligns with the region's commitment to maintaining high molecular diagnostic standards. A confluence of all these factors enables Europe hold second dominant position in the Molecular Quality Controls Market.

Asia Pacific:

Asia Pacific is estimated to grow at the highest CAGR in the molecular quality control market during the forecast period owing to booming healthcare infrastructure tackle the increasing incidences of chronic diseases among all age groups, especially growing ageing population. In addition to this, the support and funding provided by government and the multinational and regional quality control manufacturers play a crucial role in bolstering the expansion of the current market.

The region's healthcare infrastructure has grown significantly, with greater investment in sophisticated medical facilities and diagnostic capabilities. This expansion is critical for the adoption and application of new molecular diagnostics technologies, generating the need for quality controls.

Rising awareness of chronic diseases, as well as an increased emphasis on reliable diagnostics, drive the region's demand for molecular quality controls. As populations become more health-conscious, the demand for dependable and precise diagnostic instruments grows, boosting the need for quality controls.

Furthermore, the presence of both international and regional quality control producers in the Asia Pacific area improves accessibility and availability, leading to the growth of the Molecular Quality Controls Market.

Molecular Quality Controls Market: Segmentation Analysis

The Molecular Quality Controls Market is segmented based on Product, Analyte Type, Application, End User, And Geography.

Molecular Quality Controls Market, By Product

• Independent Controls
• Instrument- Specific Controls
• Polymerase Chain Reaction (PCR)
• DNA Sequencing & NGS
• Other Technologies

Based on Product, the market is segmented into Independent Controls and Instrument-Specific Controls. The independent controls segment is estimated to dominate the Molecular Quality Controls Market during the forecast period. The independent controls product segment dominates the Molecular Quality Controls Market due to its adaptability and broad applicability. Independent controls allow laboratories to evaluate and validate a variety of molecular biology procedures, such as PCR, DNA sequencing, and nucleic acid amplification. These controls take the form of well-characterized samples with known genetic traits, allowing labs to properly monitor and troubleshoot their testing processes. As a result, the dominance of the independent controls product market emphasizes its vital role in maintaining the correctness and reliability of molecular diagnostic and research results.

Molecular Quality Controls Market, By Analyte Type

• Single-Analyte Controls
• Multi-Analyte Controls

Based on Analyte Type, the market is segmented into Single-Analyte Controls and Multi-Analyte Controls. The single-analyte controls segment is estimated to dominate the market over the forecast period. Single analyte controls dominate the analyte-type segment of the Molecular Quality Controls Market due to their focus and specialization. Single analyte controls are used to assess the performance of molecular assays that target individual analytes, such as single genes or biomarkers. This precision is especially useful for assuring the quality and dependability of diagnostic procedures and research experiments targeting specific genetic markers. Therefore, the prevalence of single analyte controls emphasizes their significance in ensuring the quality and reliability of molecular testing techniques.

Molecular Quality Controls Market, By Application

• Infectious Disease Diagnostics
• Oncology Testing
• Genetic Testing
• Others

Based on Application, the market is segmented into Infectious Disease Diagnostics, Oncology Testing, Genetic Testing, and Others. Infectious disease diagnostics application is estimated to hold the majority share in the forecast period in the Molecular Quality Controls Market owing to critical role of accurate and reliable testing in managing infectious diseases. Molecular quality controls play an important role in guaranteeing the accuracy of diagnostic assays used to detect infectious agents such as bacteria, viruses, and fungus. Strong quality controls are especially important in infectious disease diagnostics since false-positive or false-negative results can have an influence on patient treatment, public health actions, and the overall success of disease management measures. Thus, the infectious disease diagnostics segment has become a focus point for the application of molecular quality standards, driving its dominance in the market.

Molecular Quality Controls Market, By End User

• Diagnostic Laboratories
• Hospitals
• IVD Manufacturers & Contract Research Organizations
• Academic & Research Institutes
• Other End Users

Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals, IVD Manufacturers & Contract Research Organizations, Academic & Research Institutes and Other End Users. Diagnostic Laboratories is estimated to hold the majority share in the forecast period in the Molecular Quality Controls Market. The diagnostic laboratories end user segment dominates the Molecular Quality Controls Market because of its vital function in delivering accurate and trustworthy diagnostic results. Diagnostic laboratories lead the way in medical testing, using molecular tools like PCR and DNA sequencing to diagnose diseases and profile patients. The dominance of the diagnostic laboratories end user segment highlights the critical role of molecular quality controls in maintaining diagnostic accuracy standards and, as a result, the overall efficacy of healthcare systems.

Key Players

• The "Molecular Quality Controls Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Abbott Laboratories, Roche Diagnostics, Thermo Fisher Scientific, Qiagen, Beckman Coulter, Siemens Healthineers, Bio-Rad Laboratories, Agilent Technologies, Danaher Corporation, Eurofins Scientific, Luminex Corporation, Promega Corporation, Myriad Genetics, Oxford Nanopore Technologies, Illumina, Inc., Invitae Corporation, Covance Laboratories, SeraCare Life Sciences, ACIES Biomedical, and ZeptoMetrix.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• In January 2024, Abbott announced a collaboration agreement with Personalis, Inc. to develop and market liquid biopsy controls for next-generation sequencing (NGS) experiments. This collaboration aims to improve the accuracy and reliability of liquid biopsy tests for cancer identification and monitoring.
• In January 2024, Roche Diagnostics introduced its new AmpliRun Control Set, which provides a comprehensive solution for quality control in qPCR experiments. This collection comprises controls for a variety of target genes, allowing laboratories to validate analytical performance and assure consistent results.
• In January 2024, Qiagen announced the availability of new QuantiTect viral load controls for SARS-CoV-2, hepatitis B virus (HBV), and cytomegalovirus. These controls address the increased need for precise monitoring of viral infections in clinical settings.
• In December 2023, The FDA authorized Luminex Corporation's xMAP Control Pak for Human Cytokine/Chemokine Panel. This clearance enables clinical laboratories to use these controls to conduct standardized quality assessments in immunoassay applications.
• In December 2023, Eurofins Scientific, a major provider of food, environmental, and pharmaceutical testing services, announced the purchase of Celsis Limited, which specializes in quick microbiological testing solutions. This acquisition solidifies Eurofins' leadership in the molecular quality control market for the food and beverage industry.

TABLE OF CONTENTS

1 INTRODUCTION OF GLOBAL MOLECULAR QUALITY CONTROLS MARKET

• 1.1 Overview of the Market
• 1.2 Scope of Report
• 1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

• 3.1 Data Mining
• 3.2 Validation
• 3.3 Primary Interviews
• 3.4 List of Data Sources

4 GLOBAL MOLECULAR QUALITY CONTROLS MARKET OUTLOOK

• 4.1 Overview
• 4.2 Market Dynamics
  • 4.2.1 Drivers
  • 4.2.2 Restraints
  • 4.2.3 Opportunities
• 4.3 Porters Five Force Model
• 4.4 Value Chain Analysis

5 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT

• 5.1 Overview
• 5.2 Instrument-Specific Controls
• 5.3 Independent Controls

6 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE

• 6.1 Overview
• 6.2 Single-Analyte Controls
• 6.3 Multi-Analyte Controls

7 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION

• 7.1 Overview
• 7.2 Infectious Disease Diagnostics
• 7.3 Oncology Testing
• 7.4 Genetic Testing
• 7.5 Others

8 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY END USER

• 8.1 Overview
• 8.2 Diagnostic Laboratories
• 8.3 Hospitals
• 8.4 IVD Manufacturers & Contract Research Organizations
• 8.5 Academic & Research Institutes
• 8.6 Other End Users

9 GLOBAL MOLECULAR QUALITY CONTROLS MARKET, BY GEOGRAPHY

• 9.1 Overview
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
  • 9.2.3 Mexico
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 U.K.
  • 9.3.3 France
  • 9.3.4 Rest of Europe
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Rest of Asia Pacific
• 9.5 Rest of the World
  • 9.5.1 Latin America
  • 9.5.2 Middle East & Africa

10 GLOBAL MOLECULAR QUALITY CONTROLS MARKET COMPETITIVE LANDSCAPE

• 10.1 Overview
• 10.2 Company Market Ranking
• 10.3 Vendor Landscape
• 10.4 Key Development Strategies

11 COMPANY PROFILES

• 11.1 Abbott Laboratories
  • 11.1.1 Overview
  • 11.1.2 Financial Performance
  • 11.1.3 Product Outlook
  • 11.1.4 Key Developments
• 11.2 Roche Diagnostics
  • 11.2.1 Overview
  • 11.2.2 Financial Performance
  • 11.2.3 Product Outlook
  • 11.2.4 Key Developments
• 11.3 Thermo Fisher Scientific
  • 11.3.1 Overview
  • 11.3.2 Financial Performance
  • 11.3.3 Product Outlook
  • 11.3.4 Key Developments
• 11.4 Qiagen
  • 11.4.1 Overview
  • 11.4.2 Financial Performance
  • 11.4.3 Product Outlook
  • 11.4.4 Key Developments
• 11.5 Beckman Coulter
  • 11.5.1 Overview
  • 11.5.2 Financial Performance
  • 11.5.3 Product Outlook
  • 11.5.4 Key Developments
• 11.6 Siemens Healthineers
  • 11.6.1 Overview
  • 11.6.2 Financial Performance
  • 11.6.3 Product Outlook
  • 11.6.4 Key Developments
• 11.7 Bio-Rad Laboratories
  • 11.7.1 Overview
  • 11.7.2 Financial Performance
  • 11.7.3 Product Outlook
  • 11.7.4 Key Developments
• 11.8 Agilent Technologies
  • 11.8.1 Overview
  • 11.8.2 Financial Performance
  • 11.8.3 Product Outlook
  • 11.8.4 Key Developments
  • 11.9 Danaher Corporation
    • 11.9.1 Overview
    • 11.9.2 Financial Performance
    • 11.9.3 Product Outlook
    • 11.9.4 Key Developments
  • 11.10 Eurofins Scientific
    • 11.10.1 Overview
    • 11.10.2 Financial Performance
    • 11.10.3 Product Outlook
    • 11.10.4 Key Developments

12 KEY DEVELOPMENTS

• 12.1 Product Launches/Developments
• 12.2 Mergers and Acquisitions
• 12.3 Business Expansions
• 12.4 Partnerships and Collaborations

13 APPENDIX

• 13.1 Related Research